/PRNewswire/ GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has.
/PRNewswire/ GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter.
GeneQuantum Raises Hundreds of Millions RMB in Series C Funding
News provided by
Share this article
Share this article
SUZHOU, China, May 18, 2021 /PRNewswire/ GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter GeneQuantum ) announced the completion of Series C fund raising of several hundreds of millions RMB. This series of fund raising is led by China Life Private Equity Investment, jointly by PICC Capital Equity Investment, Sunshine Guojian and Suzhou Wuzhong Biomedicine Industrial Park Investment. The current fund raising will provide a solid financial foundation to GeneQuantum for its global clinical development and pipeline expansion of next generation site-specific bioconjugates. Since its establishment, GeneQuantum has focused on the development of innovative bioconjugate drugs represented by Antibody-Drug-Conjugate (ADC). We possess highly differentiated ADC technology platforms, including enzyme catalyzed site-specific conjugation technology, innovative li